| blades 2004-10-30, 2:07 am |
| Interesting... stem cell transplants may become less hazardous?
http://www.pharmalive.com/News/inde...7&categoryid=15
--
Bruce (WG '97)
-------------------------------
<snip>
Cellerant Therapeutics intends to commercialize the HP-HSC as a
treatment for autoimmune and genetic diseases, beginning with lupus in
2005. HP-HSCs were shown to result in prompt engraftment in human
clinical trials involving more than 65 patients who received
myeloablative therapy, the full destruction of the stem cells in the
bone marrow which is typical in stem cell transplants. Based on animal
models, the Company believes that transplants of purified stem cells
will be curative and free of graft-versus-host disease (GVHD), the major
cause of morbidity associated with the T-cell contamination in
unpurified donor-derived stem cells.
Cellerant also intends to use its expertise in hematopoietic ontogeny
and its IP position in hematopoietic stem and progenitor cells as a
discovery platform for target screening and validation of small
molecules and biologics, both independently and with partners. Cellerant
is the exclusive worldwide licensee of the HSC patents, which are owned
by Novartis AG.
<snip>
|